Systemic therapies in the treatment of non-small-cell lung cancer brain metastases
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systemic therapies in the treatment of non-small-cell lung cancer brain metastases
Authors
Keywords
-
Journal
Future Oncology
Volume 12, Issue 8, Pages 1045-1058
Publisher
Future Medicine Ltd
Online
2016-02-18
DOI
10.2217/fon.16.17
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Discussion of the Management of Anaplastic Oligodendroglioma/Oligoastrocytoma (Both Codeleted and Nondeleted)
- (2017) Mark D. Anderson et al. Journal of the National Comprehensive Cancer Network
- The Biology of Brain Metastasis
- (2015) Isaiah J. Fidler CANCER JOURNAL
- In vivoimaging models of bone and brain metastases and pleural carcinomatosis with a novel humanEML4-ALKlung cancer cell line
- (2015) Shigeki Nanjo et al. CANCER SCIENCE
- Treatment of Brain Metastases
- (2015) Xuling Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases
- (2015) Daniel B. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- Afatinib for Erlotinib Refractory Brain Metastases in a Patient with EGFR-Mutant Non–Small-Cell Lung Cancer: Can High-Affinity TKI Substitute for High-Dose TKI?
- (2015) Akito Hata et al. Journal of Thoracic Oncology
- Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease
- (2015) Petra Hoffknecht et al. Journal of Thoracic Oncology
- Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases
- (2015) Vivek Subbiah et al. LUNG CANCER
- A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study
- (2015) J. Schuster et al. NEURO-ONCOLOGY
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy
- (2015) Yin-duo Zeng et al. Oncotarget
- Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues
- (2014) Anna Sophie Berghoff et al. ACTA NEUROPATHOLOGICA
- Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases
- (2014) Tatsushi Kodama et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
- (2014) Ted W. Johnson et al. JOURNAL OF MEDICINAL CHEMISTRY
- Vaccine therapies for patients with glioblastoma
- (2014) Eli T. Sayegh et al. JOURNAL OF NEURO-ONCOLOGY
- Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
- (2014) Walter Taal et al. LANCET ONCOLOGY
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
- (2014) Shirish M Gadgeel et al. LANCET ONCOLOGY
- BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib
- (2014) Sara D. Robinson et al. LUNG CANCER
- Role of P-Glycoprotein on the Brain Penetration and Brain Pharmacodynamic Activity of the MEK Inhibitor Cobimetinib
- (2014) Edna F. Choo et al. MOLECULAR PHARMACEUTICS
- Incidence of brain metastasis at initial presentation of lung cancer
- (2014) J. Lee Villano et al. NEURO-ONCOLOGY
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of Brain Metastases
- (2014) Rimas V. Lukas et al. ONCOLOGY
- Management of brain metastases with stereotactic radiosurgery alone versus whole brain irradiation alone versus both
- (2014) Mahmoud M El Gantery et al. Radiation Oncology
- EGF Receptor Activates MET through MAPK to Enhance Non-Small Cell Lung Carcinoma Invasion and Brain Metastasis
- (2013) J. L. Breindel et al. CANCER RESEARCH
- Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study
- (2013) Reinhard Dummer et al. EUROPEAN JOURNAL OF CANCER
- A Phase 3 Trial of Whole Brain Radiation Therapy and Stereotactic Radiosurgery Alone Versus WBRT and SRS With Temozolomide or Erlotinib for Non-Small Cell Lung Cancer and 1 to 3 Brain Metastases: Radiation Therapy Oncology Group 0320
- (2013) Paul W. Sperduto et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non–Small-Cell Lung Cancer
- (2013) James W. Welsh et al. JOURNAL OF CLINICAL ONCOLOGY
- Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patients with brain metastases of lung adenocarcinoma: a single-arm phase II clinical trial
- (2013) Xiao-xiao Dinglin et al. JOURNAL OF NEURO-ONCOLOGY
- Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases
- (2013) Priya Kumthekar et al. JOURNAL OF NEURO-ONCOLOGY
- Ineffectiveness of Crizotinib on Brain Metastases in Two Cases of Lung Adenocarcinoma with EML4-ALK Rearrangement
- (2013) Denis Maillet et al. Journal of Thoracic Oncology
- High-Dose Crizotinib for Brain Metastases Refractory to Standard-Dose Crizotinib
- (2013) Young Hak Kim et al. Journal of Thoracic Oncology
- Effective Crizotinib Schedule for Brain Metastases in ALK Rearrangement Metastatic Non–Small-Cell Lung Cancer
- (2013) Nir Peled et al. Journal of Thoracic Oncology
- ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer
- (2013) Matthias Preusser et al. LUNG CANCER
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of non-small-cell lung cancer: a multicentric Austrian phase II study
- (2013) Marco Ronald Hassler et al. WIENER KLINISCHE WOCHENSCHRIFT
- Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma
- (2013) HongQing Zhuang et al. Drug Design Development and Therapy
- EGFR,KRAS,BRAF, andHER-2molecular status in brain metastases from 77 NSCLC patients
- (2013) Claire Villalva et al. Cancer Medicine
- Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803)
- (2012) Y.- L. Wu et al. ANNALS OF ONCOLOGY
- Characterization of the inflammatory response to solid cancer metastases in the human brain
- (2012) Anna Sophie Berghoff et al. CLINICAL & EXPERIMENTAL METASTASIS
- Metallothionein 1F and 2A overexpression predicts poor outcome of non-small cell lung cancer patients
- (2012) Bozena Werynska et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)
- (2011) F. Barlesi et al. ANNALS OF ONCOLOGY
- Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)
- (2011) Gianfranco A. Pesce et al. EUROPEAN JOURNAL OF CANCER
- CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
- (2011) Daniel B. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- Rapid Radiographic and Clinical Improvement After Treatment of a MET-Amplified Recurrent Glioblastoma With a Mesenchymal-Epithelial Transition Inhibitor
- (2011) Andrew S. Chi et al. JOURNAL OF CLINICAL ONCOLOGY
- Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
- (2011) Paul W. Sperduto et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases
- (2011) Silvia Novello et al. Journal of Thoracic Oncology
- Multicenter Phase II Trial of Motexafin Gadolinium and Pemetrexed for Second-Line Treatment in Patients with Non-small Cell Lung Cancer
- (2011) Martin J. Edelman et al. Journal of Thoracic Oncology
- Whole-Brain Radiation Therapy Plus Concomitant Temozolomide for the Treatment of Brain Metastases From Non–Small-Cell Lung Cancer: A Randomized, Open-Label Phase II Study
- (2010) Daniel Chua et al. Clinical Lung Cancer
- Recursive Partitioning Analysis Groups II–III Brain Metastases of Non-small Cell Lung Cancer: A Phase II Randomized Study Comparing Two Concurrent Chemoradiotherapy Regimens
- (2010) Xavier Quantin et al. Journal of Thoracic Oncology
- Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: A multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603)
- (2010) D. Galetta et al. LUNG CANCER
- A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer
- (2009) T Neuhaus et al. BRITISH JOURNAL OF CANCER
- Phase I Study of Concurrent Whole Brain Radiotherapy and Erlotinib for Multiple Brain Metastases From Non–Small-Cell Lung Cancer
- (2009) Joline S.W. Lind et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Safety of Bevacizumab in Patients With Non–Small-Cell Lung Cancer and Brain Metastases
- (2009) Mark A. Socinski et al. JOURNAL OF CLINICAL ONCOLOGY
- Real-time imaging reveals the single steps of brain metastasis formation
- (2009) Yvonne Kienast et al. NATURE MEDICINE
- Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole‐brain radiotherapy administered first
- (2008) Dae Ho Lee et al. CANCER
- Motexafin Gadolinium Combined With Prompt Whole Brain Radiotherapy Prolongs Time to Neurologic Progression in Non–Small-Cell Lung Cancer Patients With Brain Metastases: Results of a Phase III Trial
- (2008) Minesh P. Mehta et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population
- (2008) Shenglin Ma et al. LUNG CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now